Crispr Therapeutics AG (CRSP) AI Stock Analysis

• Market Cap: $3.34B
• Dividend Yield: N/A
• Average Volume (3M): 2.28M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.05
• Revenue Growth: -86.13%
• EPS Growth: -67.29%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -1.58
• Shares Outstanding: 86,363,686
• 10 Day Avg. Volume: 2,303,779
• 30 Day Avg. Volume: 2,277,140
• PEG Ratio: 0.15
• Price to Book (P/B): 1.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -21.26
• Enterprise Value/Market Cap: 0.90
• Enterprise Value/Revenue: 4.23
• Enterprise Value/Gross Profit: -34.32
• Enterprise Value/Ebitda: -2.18
• 1Y Price Target: $68.38
• Price Target Upside: 76.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 18

Crispr Therapeutics AG's stock score reflects significant financial challenges, particularly in revenue and profitability, despite a strong balance sheet. Technical analysis suggests short-term momentum but long-term bearish trends. Valuation concerns due to a negative P/E ratio and no dividends further weigh down the score. However, a promising corporate event, the partnership with Sirius Therapeutics, offers potential growth opportunities that improve the outlook slightly.

Positive Factors

Clinical Advancements

The new siRNA approach is seen as advantageous for its rapid advancement in clinical trials.

Financial Position

CRSP ended the period with $1.9 billion in cash and equivalents.

Strategic Partnerships

Collaboration with Sirius a net positive for development.

Negative Factors

Market Competition

The factor XI field is very populated with a variety of therapeutic modalities being studied by a significant number of large pharma companies.

Product Launch Challenges

Uptake has been slow due to the intense commitment of the myeloablation conditioning regimen and the permanent nature and novelty of gene editing.

Revenue Performance

Revenue from Casgevy was below the expected figures.

Crispr Therapeutics AG Business Overview & Revenue Model

Company Description

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

How the Company Makes Money

Crispr Therapeutics AG generates revenue through a combination of collaboration agreements, milestone payments, and potential royalties from its partnerships with other biotechnology and pharmaceutical companies. Key revenue streams include collaborations with industry leaders like Vertex Pharmaceuticals, with whom it co-develops treatments for genetic diseases. The company also receives research funding and upfront payments from these collaborations, contributing to its earnings. Additionally, Crispr Therapeutics may generate future revenue from the commercialization of its proprietary therapies once they receive regulatory approval and are brought to market.

Crispr Therapeutics AG Financial Statement Overview

Summary

Crispr Therapeutics AG faces significant financial challenges, particularly in revenue generation and profitability. The income statement reveals a drastic revenue decline and negative profit margins, indicating operational struggles. However, the balance sheet is strong with substantial equity and cash reserves, providing some stability. Cash flow issues persist, with negative free cash flow and reliance on external financing.

Income Statement

Crispr Therapeutics AG has shown significant volatility in revenue and profit margins. The most recent annual report indicates a drastic revenue decline compared to previous years, with a sharp drop from 2021 to 2024. Gross and net profit margins have turned negative, highlighting operational challenges and high expenses relative to revenue. The TTM data shows a negative EBIT and EBITDA margin, indicating operational inefficiencies and ongoing financial struggles.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting stability in its capital structure. While the debt-to-equity ratio is relatively low, indicating manageable leverage, the stockholders' equity has slightly declined over the years. The balance sheet reflects a solid cash position, which is crucial for a biotech firm investing in R&D, despite the negative net income.

Cash Flow

Crispr Therapeutics AG exhibits a negative free cash flow trend, with operating cash flows consistently negative over recent years. This indicates potential liquidity challenges. The free cash flow to net income ratio is also negative, underscoring ongoing cash management issues. The cash flow from financing has been positive, which may provide temporary relief but signifies reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
35.00M	371.21M	436.00K	913.08M	543.00K
	Gross Profit
37.31M	240.96M	-109.81M	895.13M	-268.86M
	EBIT
-466.57M	-222.54M	-673.16M	373.53M	-354.44M
	EBITDA
-466.57M	-202.70M	-648.99M	391.48M	-345.25M
	Net Income Common Stockholders
-366.25M	-153.61M	-650.17M	377.66M	-348.87M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.90B	1.69B	1.82B	2.38B	1.69B
	Total Assets
2.24B	2.23B	2.24B	2.75B	1.83B
	Total Debt
223.69M	238.63M	244.02M	225.03M	61.43M
	Net Debt
-74.56M	-150.84M	32.14M	-698.00M	-1.11B
	Total Liabilities
309.95M	346.77M	367.58M	352.42M	163.73M
	Stockholders Equity
1.93B	1.88B	1.88B	2.40B	1.66B
Cash Flow		Free Cash Flow
-144.68M	-272.35M	-532.93M	457.27M	-256.72M
	Operating Cash Flow
-142.77M	-260.38M	-495.74M	538.97M	-238.37M
	Investing Cash Flow
-280.48M	374.65M	-258.65M	-1.04B	-541.17M
	Financing Cash Flow
331.98M	62.66M	38.59M	250.94M	1.02B

Crispr Therapeutics AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 38.68
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRSP, the sentiment is Positive. The current price of 38.68 is above the 20-day moving average (MA) of 37.30, above the 50-day MA of 37.90, and below the 200-day MA of 44.07, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 54.41 is Neutral, neither overbought nor oversold. The STOCH value of 83.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRSP.

Crispr Therapeutics AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	76 Outperform	$2.01B	13.37	24.71%	―	20.62%	14.08%
CRSP	57 Neutral	$3.34B	―	-19.71%	―	-86.13%	-67.29%
NTLA	54 Neutral	$938.47M	―	-57.92%	―	-13.37%	2.57%
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
ARQT	51 Neutral	$1.75B	―	-70.58%	―	100.03%	64.22%
VERV	48 Neutral	$412.73M	―	-34.26%	―	271.44%	26.65%
BEAM	45 Neutral	$1.80B	―	-38.04%	―	-82.38%	-164.76%

Crispr Therapeutics AG Corporate Events

Crispr Therapeutics AG Partners with Sirius on siRNA Tech

On May 19, 2025, CRISPR Therapeutics AG announced a collaboration agreement with Sirius Therapeutics to co-develop and commercialize siRNA technology targeting Factor XI, with an upfront consideration of $95 million. The agreement includes the development of SRSD107, a next-generation siRNA designed to inhibit coagulation factor XI, showing promising results in Phase 1 trials with potential applications in various thrombotic conditions. The collaboration aims to leverage SRSD107’s potential to reduce thrombotic events while minimizing bleeding risks, positioning it as a differentiated therapy in the market.

The most recent analyst rating on (CRSP) stock is a Hold with a $59.00 price target. To see the full list of analyst forecasts on Crispr Therapeutics AG stock, see the CRSP Stock Forecast page.

Spark’s Take on CRSP Stock

According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.

Crispr Therapeutics AG’s stock is currently facing significant financial challenges, primarily in terms of revenue generation and profitability. Despite a strong balance sheet, the negative cash flow and earnings metrics weigh heavily on the stock’s performance. Technical analysis indicates mixed signals with short-term momentum but long-term bearish trends. The valuation is unattractive due to the negative P/E ratio and lack of dividends, further impacting the stock’s appeal.

To see Spark’s full report on CRSP stock, click here.

CRISPR Therapeutics COO Julianne Bruno Resigns

On March 24, 2025, Julianne Bruno, the Chief Operating Officer of CRISPR Therapeutics, announced her resignation effective April 11, 2025, to pursue external opportunities. Her departure is not due to any disagreement with the company. Bruno has been a key figure in advancing the company’s hematology and oncology programs and other initiatives. Her resignation marks a significant transition for CRISPR Therapeutics, which continues to strengthen its position in the biopharmaceutical industry through strategic partnerships and innovative gene-editing solutions.